The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Development of CNS-Specific mTOR Inhibition for Enhanced Autophagy and Alpha-synuclein Clearance in Parkinson’s Disease
Study Rationale: A major problem in Parkinson’s disease (PD) is the buildup of a protein called alpha-synuclein, which damages brain cells. One way to help clear this toxic protein is by activating a...
-
Spring 2025 RFP: Accelerating Biological Understanding and Therapeutic Translation for PD- Biology, 2025Determining PINK1 and PRKN Enzyme Activities In Vivo.
Study Rationale: In Parkinson’s disease, loss of nigral dopaminergic neurons leads to motor symptoms. PINK1 and PRKN are both proteins involved in mitochondrial quality control, which when carrying...
-
Summer 2025 RFP: Accelerating Biological Understanding and Translational Approaches for PD Program - Biology, 2025Treatment of APOE4-associated Cognitive Decline in Parkinson’s Disease by an Adeno-associated Virus Coding for the Combined APOE2 and APOE-Christchurch Variants
-
Spring 2025 RFA: Molecular MRI Biomarker Program, 2025Molecular Magnetic Resonance Imaging (mMRI) GlioScope: A Comprehensive Approach to Noninvasive Profiling of Neuroinflammation in Pre-clinical Models of Parkinson’s Disease.
Study Rationale: The biology of the spread of Parkinson’s disease (PD) is very complicated and not yet well understood. However, one of the key drivers has been identified as neuroinflammation and the...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Development of Selective CaV1.3 Inhibitors as a Disease-modifying Therapy for Parkinson’s Disease
Study Rationale: We seek to develop an oral medication that will protect dopamine neurons whose loss is thought to be the cause Parkinson’s disease (PD). Observational clinical evidence suggests that...
-
Fall 2025 RFP: Data Advice To Action - DATA-PD, 2025Machine Leaning Based Proteomics Integration Reveals Biomarkers of Disease Pathology and Longitudinal Progression in PD and DLB
Study Rationale: Parkinson’s disease is usually diagnosed by symptoms, but the biological changes driving the disease begin many years earlier. While new tests that detect abnormal alpha-synuclein are...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.